Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-finding study of subcutaneous spesolimab in moderate to severe palmoplantar pustulosis
jRCT2080224819Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Palmoplantar Pustular Psoriasis (PPPP) comparing Spesolimab arm with Placebo arm (2 arms). Started Aug 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on jRCT2080224819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224819.